---
title: Whitepaper - The Latest MHC Class I & II Deficient In Vivo Platform Humanized with PBMCs
description: Whitepaper - The Latest MHC Class I & II Deficient In Vivo Platform Humanized with PBMCs
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![Jackson Labs landing page header\_1425px](https://info.edifydigitalmedia.com/hubfs/Jackson%20Labs%20landing%20page%20header_1425px.jpg "Jackson Labs landing page header_1425px")

# WHITEPAPER The Latest MHC Class I & II Deficient In Vivo Platform Humanised with PBMCs

 

![Jakson\_Labs\_asset\_image\_CMP 0922\_200px](https://info.edifydigitalmedia.com/hubfs/Jakson_Labs_asset_image_CMP%200922_200px.jpg "Jakson_Labs_asset_image_CMP 0922_200px")

**In this whitepaper you'll learn:**

- The benefits of the JAX NSGTM-MHC I/II KO mouse platform humanised with pre-characterised PBMCs
- How this platform can support a wide range of immunological studies, especially those containing T cells responses
- The versatility of this platform to various research disciplines

*Brought to you by* 

*![Jackson-Labs-Logo\_400px](https://info.edifydigitalmedia.com/hs-fs/hubfs/Jackson-Labs-Logo_400px.png?width=188&name=Jackson-Labs-Logo_400px.png)*

### Download the Whitepaper

## Copyright 2022 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions